Anti-VEGF Market Size, Trends & Growth Analysis

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Anti-VEGF Market Size Analysis

Global Anti-VEGF Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Eylea
  1. By Value
3. Lucentis
  1. By Value
4. Beovu
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Macular Edema
  1. By Value
3. Diabetic Retinopathy
  1. By Value
4. Retinal Vein Occlusion
  1. By Value
5. Age-Related Macular Degeneration
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Small Molecules
  1. By Value
  2. Pazopanib
    1. Pazopanib By Value
  3. Sunitinib
    1. Sunitinib By Value
  4. Sorafenib
    1. Sorafenib By Value
  5. Regorafenib
    1. Regorafenib By Value
  6. Cabozantinib
    1. Cabozantinib By Value
  7. Lenvatinib
    1. Lenvatinib By Value
  8. Ponatinib
    1. Ponatinib By Value
  9. Axitinib
    1. Axitinib By Value
  10. Tivozanib
    1. Tivozanib By Value
  11. Vandetanib
    1. Vandetanib By Value
  12. Anlotinib
    1. Anlotinib By Value
  13. Apatinib
    1. Apatinib By Value
  14. Fruquintinib
    1. Fruquintinib By Value
  15. Surufatinib
    1. Surufatinib By Value
3. Biologics
  1. By Value
  2. Bevacizumab
    1. Bevacizumab By Value
  3. Aflibercept
    1. Aflibercept By Value
  4. Ramucirumab
    1. Ramucirumab By Value
By Type
1. Introduction
  1. Type By Value
2. VEGF-A Inhibitors
  1. By Value
3. VEGF-B Inhibitors
  1. By Value
4. VEGF-C Inhibitors
  1. By Value
5. Placenta Growth Factor Inhibitors
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals
  1. By Value
3. Specialty Clinics
  1. By Value
4. Mail Order Pharmacies
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Eylea
  1. By Value
3. Lucentis
  1. By Value
4. Beovu
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Macular Edema
  1. By Value
3. Diabetic Retinopathy
  1. By Value
4. Retinal Vein Occlusion
  1. By Value
5. Age-Related Macular Degeneration
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Small Molecules
  1. By Value
  2. Pazopanib
    1. Pazopanib By Value
  3. Sunitinib
    1. Sunitinib By Value
  4. Sorafenib
    1. Sorafenib By Value
  5. Regorafenib
    1. Regorafenib By Value
  6. Cabozantinib
    1. Cabozantinib By Value
  7. Lenvatinib
    1. Lenvatinib By Value
  8. Ponatinib
    1. Ponatinib By Value
  9. Axitinib
    1. Axitinib By Value
  10. Tivozanib
    1. Tivozanib By Value
  11. Vandetanib
    1. Vandetanib By Value
  12. Anlotinib
    1. Anlotinib By Value
  13. Apatinib
    1. Apatinib By Value
  14. Fruquintinib
    1. Fruquintinib By Value
  15. Surufatinib
    1. Surufatinib By Value
3. Biologics
  1. By Value
  2. Bevacizumab
    1. Bevacizumab By Value
  3. Aflibercept
    1. Aflibercept By Value
  4. Ramucirumab
    1. Ramucirumab By Value
By Type
1. Introduction
  1. Type By Value
2. VEGF-A Inhibitors
  1. By Value
3. VEGF-B Inhibitors
  1. By Value
4. VEGF-C Inhibitors
  1. By Value
5. Placenta Growth Factor Inhibitors
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals
  1. By Value
3. Specialty Clinics
  1. By Value
4. Mail Order Pharmacies
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Eylea
    1. By Value
  3. Lucentis
    1. By Value
  4. Beovu
    1. By Value
2. By Disease
  1. Introduction
    1. Disease By Value
  2. Macular Edema
    1. By Value
  3. Diabetic Retinopathy
    1. By Value
  4. Retinal Vein Occlusion
    1. By Value
  5. Age-Related Macular Degeneration
    1. By Value
3. By Drug
  1. Introduction
    1. Drug By Value
  2. Small Molecules
    1. By Value
    2. Pazopanib
      1. Pazopanib By Value
    3. Sunitinib
      1. Sunitinib By Value
    4. Sorafenib
      1. Sorafenib By Value
    5. Regorafenib
      1. Regorafenib By Value
    6. Cabozantinib
      1. Cabozantinib By Value
    7. Lenvatinib
      1. Lenvatinib By Value
    8. Ponatinib
      1. Ponatinib By Value
    9. Axitinib
      1. Axitinib By Value
    10. Tivozanib
      1. Tivozanib By Value
    11. Vandetanib
      1. Vandetanib By Value
    12. Anlotinib
      1. Anlotinib By Value
    13. Apatinib
      1. Apatinib By Value
    14. Fruquintinib
      1. Fruquintinib By Value
    15. Surufatinib
      1. Surufatinib By Value
  3. Biologics
    1. By Value
    2. Bevacizumab
      1. Bevacizumab By Value
    3. Aflibercept
      1. Aflibercept By Value
    4. Ramucirumab
      1. Ramucirumab By Value
4. By Type
  1. Introduction
    1. Type By Value
  2. VEGF-A Inhibitors
    1. By Value
  3. VEGF-B Inhibitors
    1. By Value
  4. VEGF-C Inhibitors
    1. By Value
  5. Placenta Growth Factor Inhibitors
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Specialty Clinics
    1. By Value
  4. Mail Order Pharmacies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Eylea
  1. By Value
3. Lucentis
  1. By Value
4. Beovu
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Macular Edema
  1. By Value
3. Diabetic Retinopathy
  1. By Value
4. Retinal Vein Occlusion
  1. By Value
5. Age-Related Macular Degeneration
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Small Molecules
  1. By Value
  2. Pazopanib
    1. Pazopanib By Value
  3. Sunitinib
    1. Sunitinib By Value
  4. Sorafenib
    1. Sorafenib By Value
  5. Regorafenib
    1. Regorafenib By Value
  6. Cabozantinib
    1. Cabozantinib By Value
  7. Lenvatinib
    1. Lenvatinib By Value
  8. Ponatinib
    1. Ponatinib By Value
  9. Axitinib
    1. Axitinib By Value
  10. Tivozanib
    1. Tivozanib By Value
  11. Vandetanib
    1. Vandetanib By Value
  12. Anlotinib
    1. Anlotinib By Value
  13. Apatinib
    1. Apatinib By Value
  14. Fruquintinib
    1. Fruquintinib By Value
  15. Surufatinib
    1. Surufatinib By Value
3. Biologics
  1. By Value
  2. Bevacizumab
    1. Bevacizumab By Value
  3. Aflibercept
    1. Aflibercept By Value
  4. Ramucirumab
    1. Ramucirumab By Value
By Type
1. Introduction
  1. Type By Value
2. VEGF-A Inhibitors
  1. By Value
3. VEGF-B Inhibitors
  1. By Value
4. VEGF-C Inhibitors
  1. By Value
5. Placenta Growth Factor Inhibitors
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals
  1. By Value
3. Specialty Clinics
  1. By Value
4. Mail Order Pharmacies
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Eylea
    1. By Value
  3. Lucentis
    1. By Value
  4. Beovu
    1. By Value
2. By Disease
  1. Introduction
    1. Disease By Value
  2. Macular Edema
    1. By Value
  3. Diabetic Retinopathy
    1. By Value
  4. Retinal Vein Occlusion
    1. By Value
  5. Age-Related Macular Degeneration
    1. By Value
3. By Drug
  1. Introduction
    1. Drug By Value
  2. Small Molecules
    1. By Value
    2. Pazopanib
      1. Pazopanib By Value
    3. Sunitinib
      1. Sunitinib By Value
    4. Sorafenib
      1. Sorafenib By Value
    5. Regorafenib
      1. Regorafenib By Value
    6. Cabozantinib
      1. Cabozantinib By Value
    7. Lenvatinib
      1. Lenvatinib By Value
    8. Ponatinib
      1. Ponatinib By Value
    9. Axitinib
      1. Axitinib By Value
    10. Tivozanib
      1. Tivozanib By Value
    11. Vandetanib
      1. Vandetanib By Value
    12. Anlotinib
      1. Anlotinib By Value
    13. Apatinib
      1. Apatinib By Value
    14. Fruquintinib
      1. Fruquintinib By Value
    15. Surufatinib
      1. Surufatinib By Value
  3. Biologics
    1. By Value
    2. Bevacizumab
      1. Bevacizumab By Value
    3. Aflibercept
      1. Aflibercept By Value
    4. Ramucirumab
      1. Ramucirumab By Value
4. By Type
  1. Introduction
    1. Type By Value
  2. VEGF-A Inhibitors
    1. By Value
  3. VEGF-B Inhibitors
    1. By Value
  4. VEGF-C Inhibitors
    1. By Value
  5. Placenta Growth Factor Inhibitors
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Specialty Clinics
    1. By Value
  4. Mail Order Pharmacies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Eylea
  1. By Value
3. Lucentis
  1. By Value
4. Beovu
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Macular Edema
  1. By Value
3. Diabetic Retinopathy
  1. By Value
4. Retinal Vein Occlusion
  1. By Value
5. Age-Related Macular Degeneration
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Small Molecules
  1. By Value
  2. Pazopanib
    1. Pazopanib By Value
  3. Sunitinib
    1. Sunitinib By Value
  4. Sorafenib
    1. Sorafenib By Value
  5. Regorafenib
    1. Regorafenib By Value
  6. Cabozantinib
    1. Cabozantinib By Value
  7. Lenvatinib
    1. Lenvatinib By Value
  8. Ponatinib
    1. Ponatinib By Value
  9. Axitinib
    1. Axitinib By Value
  10. Tivozanib
    1. Tivozanib By Value
  11. Vandetanib
    1. Vandetanib By Value
  12. Anlotinib
    1. Anlotinib By Value
  13. Apatinib
    1. Apatinib By Value
  14. Fruquintinib
    1. Fruquintinib By Value
  15. Surufatinib
    1. Surufatinib By Value
3. Biologics
  1. By Value
  2. Bevacizumab
    1. Bevacizumab By Value
  3. Aflibercept
    1. Aflibercept By Value
  4. Ramucirumab
    1. Ramucirumab By Value
By Type
1. Introduction
  1. Type By Value
2. VEGF-A Inhibitors
  1. By Value
3. VEGF-B Inhibitors
  1. By Value
4. VEGF-C Inhibitors
  1. By Value
5. Placenta Growth Factor Inhibitors
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals
  1. By Value
3. Specialty Clinics
  1. By Value
4. Mail Order Pharmacies
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Eylea
    1. By Value
  3. Lucentis
    1. By Value
  4. Beovu
    1. By Value
2. By Disease
  1. Introduction
    1. Disease By Value
  2. Macular Edema
    1. By Value
  3. Diabetic Retinopathy
    1. By Value
  4. Retinal Vein Occlusion
    1. By Value
  5. Age-Related Macular Degeneration
    1. By Value
3. By Drug
  1. Introduction
    1. Drug By Value
  2. Small Molecules
    1. By Value
    2. Pazopanib
      1. Pazopanib By Value
    3. Sunitinib
      1. Sunitinib By Value
    4. Sorafenib
      1. Sorafenib By Value
    5. Regorafenib
      1. Regorafenib By Value
    6. Cabozantinib
      1. Cabozantinib By Value
    7. Lenvatinib
      1. Lenvatinib By Value
    8. Ponatinib
      1. Ponatinib By Value
    9. Axitinib
      1. Axitinib By Value
    10. Tivozanib
      1. Tivozanib By Value
    11. Vandetanib
      1. Vandetanib By Value
    12. Anlotinib
      1. Anlotinib By Value
    13. Apatinib
      1. Apatinib By Value
    14. Fruquintinib
      1. Fruquintinib By Value
    15. Surufatinib
      1. Surufatinib By Value
  3. Biologics
    1. By Value
    2. Bevacizumab
      1. Bevacizumab By Value
    3. Aflibercept
      1. Aflibercept By Value
    4. Ramucirumab
      1. Ramucirumab By Value
4. By Type
  1. Introduction
    1. Type By Value
  2. VEGF-A Inhibitors
    1. By Value
  3. VEGF-B Inhibitors
    1. By Value
  4. VEGF-C Inhibitors
    1. By Value
  5. Placenta Growth Factor Inhibitors
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Specialty Clinics
    1. By Value
  4. Mail Order Pharmacies
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Eylea
  1. By Value
3. Lucentis
  1. By Value
4. Beovu
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Macular Edema
  1. By Value
3. Diabetic Retinopathy
  1. By Value
4. Retinal Vein Occlusion
  1. By Value
5. Age-Related Macular Degeneration
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Small Molecules
  1. By Value
  2. Pazopanib
    1. Pazopanib By Value
  3. Sunitinib
    1. Sunitinib By Value
  4. Sorafenib
    1. Sorafenib By Value
  5. Regorafenib
    1. Regorafenib By Value
  6. Cabozantinib
    1. Cabozantinib By Value
  7. Lenvatinib
    1. Lenvatinib By Value
  8. Ponatinib
    1. Ponatinib By Value
  9. Axitinib
    1. Axitinib By Value
  10. Tivozanib
    1. Tivozanib By Value
  11. Vandetanib
    1. Vandetanib By Value
  12. Anlotinib
    1. Anlotinib By Value
  13. Apatinib
    1. Apatinib By Value
  14. Fruquintinib
    1. Fruquintinib By Value
  15. Surufatinib
    1. Surufatinib By Value
3. Biologics
  1. By Value
  2. Bevacizumab
    1. Bevacizumab By Value
  3. Aflibercept
    1. Aflibercept By Value
  4. Ramucirumab
    1. Ramucirumab By Value
By Type
1. Introduction
  1. Type By Value
2. VEGF-A Inhibitors
  1. By Value
3. VEGF-B Inhibitors
  1. By Value
4. VEGF-C Inhibitors
  1. By Value
5. Placenta Growth Factor Inhibitors
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals
  1. By Value
3. Specialty Clinics
  1. By Value
4. Mail Order Pharmacies
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Eylea
    1. By Value
  3. Lucentis
    1. By Value
  4. Beovu
    1. By Value
2. By Disease
  1. Introduction
    1. Disease By Value
  2. Macular Edema
    1. By Value
  3. Diabetic Retinopathy
    1. By Value
  4. Retinal Vein Occlusion
    1. By Value
  5. Age-Related Macular Degeneration
    1. By Value
3. By Drug
  1. Introduction
    1. Drug By Value
  2. Small Molecules
    1. By Value
    2. Pazopanib
      1. Pazopanib By Value
    3. Sunitinib
      1. Sunitinib By Value
    4. Sorafenib
      1. Sorafenib By Value
    5. Regorafenib
      1. Regorafenib By Value
    6. Cabozantinib
      1. Cabozantinib By Value
    7. Lenvatinib
      1. Lenvatinib By Value
    8. Ponatinib
      1. Ponatinib By Value
    9. Axitinib
      1. Axitinib By Value
    10. Tivozanib
      1. Tivozanib By Value
    11. Vandetanib
      1. Vandetanib By Value
    12. Anlotinib
      1. Anlotinib By Value
    13. Apatinib
      1. Apatinib By Value
    14. Fruquintinib
      1. Fruquintinib By Value
    15. Surufatinib
      1. Surufatinib By Value
  3. Biologics
    1. By Value
    2. Bevacizumab
      1. Bevacizumab By Value
    3. Aflibercept
      1. Aflibercept By Value
    4. Ramucirumab
      1. Ramucirumab By Value
4. By Type
  1. Introduction
    1. Type By Value
  2. VEGF-A Inhibitors
    1. By Value
  3. VEGF-B Inhibitors
    1. By Value
  4. VEGF-C Inhibitors
    1. By Value
  5. Placenta Growth Factor Inhibitors
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Specialty Clinics
    1. By Value
  4. Mail Order Pharmacies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Eylea
  1. By Value
3. Lucentis
  1. By Value
4. Beovu
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Macular Edema
  1. By Value
3. Diabetic Retinopathy
  1. By Value
4. Retinal Vein Occlusion
  1. By Value
5. Age-Related Macular Degeneration
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Small Molecules
  1. By Value
  2. Pazopanib
    1. Pazopanib By Value
  3. Sunitinib
    1. Sunitinib By Value
  4. Sorafenib
    1. Sorafenib By Value
  5. Regorafenib
    1. Regorafenib By Value
  6. Cabozantinib
    1. Cabozantinib By Value
  7. Lenvatinib
    1. Lenvatinib By Value
  8. Ponatinib
    1. Ponatinib By Value
  9. Axitinib
    1. Axitinib By Value
  10. Tivozanib
    1. Tivozanib By Value
  11. Vandetanib
    1. Vandetanib By Value
  12. Anlotinib
    1. Anlotinib By Value
  13. Apatinib
    1. Apatinib By Value
  14. Fruquintinib
    1. Fruquintinib By Value
  15. Surufatinib
    1. Surufatinib By Value
3. Biologics
  1. By Value
  2. Bevacizumab
    1. Bevacizumab By Value
  3. Aflibercept
    1. Aflibercept By Value
  4. Ramucirumab
    1. Ramucirumab By Value
By Type
1. Introduction
  1. Type By Value
2. VEGF-A Inhibitors
  1. By Value
3. VEGF-B Inhibitors
  1. By Value
4. VEGF-C Inhibitors
  1. By Value
5. Placenta Growth Factor Inhibitors
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals
  1. By Value
3. Specialty Clinics
  1. By Value
4. Mail Order Pharmacies
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Eylea
    1. By Value
  3. Lucentis
    1. By Value
  4. Beovu
    1. By Value
2. By Disease
  1. Introduction
    1. Disease By Value
  2. Macular Edema
    1. By Value
  3. Diabetic Retinopathy
    1. By Value
  4. Retinal Vein Occlusion
    1. By Value
  5. Age-Related Macular Degeneration
    1. By Value
3. By Drug
  1. Introduction
    1. Drug By Value
  2. Small Molecules
    1. By Value
    2. Pazopanib
      1. Pazopanib By Value
    3. Sunitinib
      1. Sunitinib By Value
    4. Sorafenib
      1. Sorafenib By Value
    5. Regorafenib
      1. Regorafenib By Value
    6. Cabozantinib
      1. Cabozantinib By Value
    7. Lenvatinib
      1. Lenvatinib By Value
    8. Ponatinib
      1. Ponatinib By Value
    9. Axitinib
      1. Axitinib By Value
    10. Tivozanib
      1. Tivozanib By Value
    11. Vandetanib
      1. Vandetanib By Value
    12. Anlotinib
      1. Anlotinib By Value
    13. Apatinib
      1. Apatinib By Value
    14. Fruquintinib
      1. Fruquintinib By Value
    15. Surufatinib
      1. Surufatinib By Value
  3. Biologics
    1. By Value
    2. Bevacizumab
      1. Bevacizumab By Value
    3. Aflibercept
      1. Aflibercept By Value
    4. Ramucirumab
      1. Ramucirumab By Value
4. By Type
  1. Introduction
    1. Type By Value
  2. VEGF-A Inhibitors
    1. By Value
  3. VEGF-B Inhibitors
    1. By Value
  4. VEGF-C Inhibitors
    1. By Value
  5. Placenta Growth Factor Inhibitors
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Specialty Clinics
    1. By Value
  4. Mail Order Pharmacies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Anti-VEGF Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

F. Hoffmann-La Roche Ltd.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Amgen Inc.
Pfizer Inc.
Xbrane Biopharma AB
Allergan
Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc. (Mylan)

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment